Loading…
The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review
Background The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have em...
Saved in:
Published in: | Journal of clinical laboratory analysis 2024-01, Vol.38 (1-2), p.e25005-n/a |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423 |
---|---|
cites | cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423 |
container_end_page | n/a |
container_issue | 1-2 |
container_start_page | e25005 |
container_title | Journal of clinical laboratory analysis |
container_volume | 38 |
creator | Hoseinnezhad, Taraneh Soltani, Nasrin Ziarati, Sarina Behboudi, Emad Mousavi, Mohammad Javad |
description | Background
The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes.
Methods
In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity.
Results
Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations.
Conclusion
Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants.
This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effe |
doi_str_mv | 10.1002/jcla.25005 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10829690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2917552913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</originalsourceid><addsrcrecordid>eNp9kctOGzEUhi1UBCllwwNUlthUVQd8GSd2N1WUXgBFYhN1a3k8Z4IjZ5zaM0HZ9RF4Rp6kDgEELLrxsfR_-nSOfoROKDmjhLDzhfXmjAlCxB4aUKJkwSQT79CASDkqJKH8EL1PaUEIkYoOD9AhzzmVlA7QfHYDOAYPODT4YjrGc2ihcxavTXSm7RJ2LZ5c_778fv_3jiqc-mRh1bnKeddtvuAEa4gPP9PWeBliZ7bBV5xNPlTG4whrB7cf0H5jfILjx3mEZj9_zCYXxfT61-VkPC1sWSpRVJzWDS-JFaUsVUNEoyhYVSnZlLVgktd0yC2w2jaVGVXDEbc54awSoGTJ-BH6ttOu-moJtYW2i8brVXRLEzc6GKdfJ6270fOw1pRIpoaKZMOnR0MMf3pInV66fLL3poXQJ80UHQmRX57R0zfoIvSxzedlihEquRJlpj7vKBtDShGa520o0dv-9LY__dBfhj--3P8ZfSosA3QH3DoPm_-o9NVkOt5J_wFWPKXe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920183954</pqid></control><display><type>article</type><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><source>Open Access: PubMed Central</source><source>Wiley_OA刊</source><source>ProQuest - Publicly Available Content Database</source><creator>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</creator><creatorcontrib>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</creatorcontrib><description>Background
The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes.
Methods
In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity.
Results
Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations.
Conclusion
Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants.
This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</description><identifier>ISSN: 0887-8013</identifier><identifier>ISSN: 1098-2825</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.25005</identifier><identifier>PMID: 38251811</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Alleles ; Antigens ; COVID-19 ; COVID-19 - genetics ; COVID-19 vaccines ; disease outcomes ; Disease transmission ; ethnicity ; Gene frequency ; Gene Frequency - genetics ; Genetic diversity ; genetic variation ; Histocompatibility antigen HLA ; HLA alleles ; Humans ; Immune system ; Lymphocytes ; Mortality ; Pandemics ; Peptides ; Polymorphism ; Population genetics ; Proteins ; Review ; SARS-CoV-2 - genetics ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; severity ; Signal transduction ; susceptibility ; Therapeutic applications ; Viruses</subject><ispartof>Journal of clinical laboratory analysis, 2024-01, Vol.38 (1-2), p.e25005-n/a</ispartof><rights>2024 The Authors. published by Wiley Periodicals LLC.</rights><rights>2024 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</citedby><cites>FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</cites><orcidid>0000-0002-1296-4558 ; 0000-0002-8971-0775</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2920183954/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2920183954?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11560,25751,27922,27923,37010,37011,44588,46050,46474,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38251811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoseinnezhad, Taraneh</creatorcontrib><creatorcontrib>Soltani, Nasrin</creatorcontrib><creatorcontrib>Ziarati, Sarina</creatorcontrib><creatorcontrib>Behboudi, Emad</creatorcontrib><creatorcontrib>Mousavi, Mohammad Javad</creatorcontrib><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background
The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes.
Methods
In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity.
Results
Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations.
Conclusion
Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants.
This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</description><subject>Alleles</subject><subject>Antigens</subject><subject>COVID-19</subject><subject>COVID-19 - genetics</subject><subject>COVID-19 vaccines</subject><subject>disease outcomes</subject><subject>Disease transmission</subject><subject>ethnicity</subject><subject>Gene frequency</subject><subject>Gene Frequency - genetics</subject><subject>Genetic diversity</subject><subject>genetic variation</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA alleles</subject><subject>Humans</subject><subject>Immune system</subject><subject>Lymphocytes</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Peptides</subject><subject>Polymorphism</subject><subject>Population genetics</subject><subject>Proteins</subject><subject>Review</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>severity</subject><subject>Signal transduction</subject><subject>susceptibility</subject><subject>Therapeutic applications</subject><subject>Viruses</subject><issn>0887-8013</issn><issn>1098-2825</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kctOGzEUhi1UBCllwwNUlthUVQd8GSd2N1WUXgBFYhN1a3k8Z4IjZ5zaM0HZ9RF4Rp6kDgEELLrxsfR_-nSOfoROKDmjhLDzhfXmjAlCxB4aUKJkwSQT79CASDkqJKH8EL1PaUEIkYoOD9AhzzmVlA7QfHYDOAYPODT4YjrGc2ihcxavTXSm7RJ2LZ5c_778fv_3jiqc-mRh1bnKeddtvuAEa4gPP9PWeBliZ7bBV5xNPlTG4whrB7cf0H5jfILjx3mEZj9_zCYXxfT61-VkPC1sWSpRVJzWDS-JFaUsVUNEoyhYVSnZlLVgktd0yC2w2jaVGVXDEbc54awSoGTJ-BH6ttOu-moJtYW2i8brVXRLEzc6GKdfJ6270fOw1pRIpoaKZMOnR0MMf3pInV66fLL3poXQJ80UHQmRX57R0zfoIvSxzedlihEquRJlpj7vKBtDShGa520o0dv-9LY__dBfhj--3P8ZfSosA3QH3DoPm_-o9NVkOt5J_wFWPKXe</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Hoseinnezhad, Taraneh</creator><creator>Soltani, Nasrin</creator><creator>Ziarati, Sarina</creator><creator>Behboudi, Emad</creator><creator>Mousavi, Mohammad Javad</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1296-4558</orcidid><orcidid>https://orcid.org/0000-0002-8971-0775</orcidid></search><sort><creationdate>202401</creationdate><title>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</title><author>Hoseinnezhad, Taraneh ; Soltani, Nasrin ; Ziarati, Sarina ; Behboudi, Emad ; Mousavi, Mohammad Javad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alleles</topic><topic>Antigens</topic><topic>COVID-19</topic><topic>COVID-19 - genetics</topic><topic>COVID-19 vaccines</topic><topic>disease outcomes</topic><topic>Disease transmission</topic><topic>ethnicity</topic><topic>Gene frequency</topic><topic>Gene Frequency - genetics</topic><topic>Genetic diversity</topic><topic>genetic variation</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA alleles</topic><topic>Humans</topic><topic>Immune system</topic><topic>Lymphocytes</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Peptides</topic><topic>Polymorphism</topic><topic>Population genetics</topic><topic>Proteins</topic><topic>Review</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>severity</topic><topic>Signal transduction</topic><topic>susceptibility</topic><topic>Therapeutic applications</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoseinnezhad, Taraneh</creatorcontrib><creatorcontrib>Soltani, Nasrin</creatorcontrib><creatorcontrib>Ziarati, Sarina</creatorcontrib><creatorcontrib>Behboudi, Emad</creatorcontrib><creatorcontrib>Mousavi, Mohammad Javad</creatorcontrib><collection>Wiley_OA刊</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoseinnezhad, Taraneh</au><au>Soltani, Nasrin</au><au>Ziarati, Sarina</au><au>Behboudi, Emad</au><au>Mousavi, Mohammad Javad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2024-01</date><risdate>2024</risdate><volume>38</volume><issue>1-2</issue><spage>e25005</spage><epage>n/a</epage><pages>e25005-n/a</pages><issn>0887-8013</issn><issn>1098-2825</issn><eissn>1098-2825</eissn><abstract>Background
The COVID‐19 pandemic has had a profound global impact, with variations in susceptibility, severity, and mortality rates across different regions. While many factors can contribute to the spread and impact of the disease, specifically human leukocyte antigen (HLA) genetic variants have emerged as potential contributors to COVID‐19 outcomes.
Methods
In this comprehensive narrative review, we conducted a thorough literature search to identify relevant studies investigating the association between HLA genetic variants and COVID‐19 outcomes. Additionally, we analyzed allelic frequency data from diverse populations to assess differences in COVID‐19 incidence and severity.
Results
Our review provides insights into the immunological mechanisms involving HLA‐mediated responses to COVID‐19 and highlights potential research directions and therapeutic interventions. We found evidence suggesting that certain HLA alleles, such as HLA‐A02, may confer a lower risk of COVID‐19, while others, like HLA‐C04, may increase the risk of severe symptoms and mortality. Furthermore, our analysis of allele frequency distributions revealed significant variations among different populations.
Conclusion
Considering host genetic variations, particularly HLA genetic variants, is crucial for understanding COVID‐19 susceptibility and severity. These findings have implications for personalized treatment and interventions based on an individual's genetic profile. However, further research is needed to unravel the precise mechanisms underlying the observed associations and explore the potential for targeted therapies or preventive measures based on HLA genetic variants.
This figure presents a worldwide vision illustrating the relationship between the frequencies of HLA‐C04 and HLA‐A02 alleles and their respective associations with COVID‐19 susceptibility and mortality rates across different regions. The darker shaded areas represent regions with moderate‐to‐high frequencies of selected alleles and higher rates of susceptibility and mortality from COVID‐19. However, there are exceptions, such as China, where despite a higher frequency of HLA‐C04, lower incidence and mortality rates are observed. This suggests the influence of factors beyond host genetics, including government policies (e.g., Zero‐COVID‐19 policy), timely implementation of quarantine measures, access to vaccines and treatments, and well‐equipped medical facilities. Similarly, the figure highlights the protective effect of HLA‐A02 allele, which is associated with lower COVID‐19 susceptibility and reduced mortality rates. However, variations in this protective effect are observed, possibly due to the aforementioned contributing factors.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>38251811</pmid><doi>10.1002/jcla.25005</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1296-4558</orcidid><orcidid>https://orcid.org/0000-0002-8971-0775</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0887-8013 |
ispartof | Journal of clinical laboratory analysis, 2024-01, Vol.38 (1-2), p.e25005-n/a |
issn | 0887-8013 1098-2825 1098-2825 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10829690 |
source | Open Access: PubMed Central; Wiley_OA刊; ProQuest - Publicly Available Content Database |
subjects | Alleles Antigens COVID-19 COVID-19 - genetics COVID-19 vaccines disease outcomes Disease transmission ethnicity Gene frequency Gene Frequency - genetics Genetic diversity genetic variation Histocompatibility antigen HLA HLA alleles Humans Immune system Lymphocytes Mortality Pandemics Peptides Polymorphism Population genetics Proteins Review SARS-CoV-2 - genetics SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 severity Signal transduction susceptibility Therapeutic applications Viruses |
title | The role of HLA genetic variants in COVID‐19 susceptibility, severity, and mortality: A global review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A43%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20HLA%20genetic%20variants%20in%20COVID%E2%80%9019%20susceptibility,%20severity,%20and%20mortality:%20A%20global%20review&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Hoseinnezhad,%20Taraneh&rft.date=2024-01&rft.volume=38&rft.issue=1-2&rft.spage=e25005&rft.epage=n/a&rft.pages=e25005-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.25005&rft_dat=%3Cproquest_pubme%3E2917552913%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4495-b31df340c54849f05f91ec9b98f4d5283d163ce2dcfba7b673c8f432b5e98423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2920183954&rft_id=info:pmid/38251811&rfr_iscdi=true |